<DOC>
	<DOCNO>NCT02472938</DOCNO>
	<brief_summary>The primary objective study assess early efficacy treatment BG00012 ( dimethyl fumarate ) 240 mg twice daily ( BID ) brain newly diagnose naive-to-treatment patient relapsing-remitting multiple sclerosis ( RRMS ) . The Secondary objective establish time course beneficial effect BG00012 240 mg BID 24 week evaluate safety BG00012 .</brief_summary>
	<brief_title>Study Explore Onset Efficacy Magnetic Resonance Disease Activity BG00012 ( Dimethyl Fumarate ) Patients With Relapsing remitTing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Participants RRMS ( McDonald criterion , 2010 ) accept current injectable firstline DMTs . Multiple sclerosis ( MS ) onset within one year enrolment ≥ 1 Gd+ lesion brain MRI scan perform within three month beforeenrolment . No previous disease modify and/or immunosuppressive treatment MS. Must baseline EDSS 0.0 5.0 , inclusive . · Women childbearing potential ( i.e . postmenopausal least 1 year ) men must practice effective contraception ( defined Investigator ) study willing able continue contraception 30 day last dose study treatment . Primary progressive , secondary progressive , progressive relapsing MS , define Lublin Reingold ( Lublin Reingold 1996 ) Previous disease modify and/or immunosuppressive treatment MS , include Tcell Tcell receptor vaccination , therapeutic monoclonal antibody , Mitoxantrone , Cyclophosphamide Previous treatment Fumaderm® , dimethyl fumarate fumarates History malignancy ( except basal cell carcinoma completely excise prior study enrollment ) History severe allergic anaphylactic reaction know drug hypersensitivity.Known allergy/hypersensitivity Gadolinium . History abnormal laboratory result indicative significant endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , renal , and/or major disease opinion Investigator would preclude participation clinical trial . History positive test result screen human immunodeficiency virus ( HIV ) .Positive hepatitis C antibody and/or positive hepatitis B surface antigen ( HBsAg ) screening . History drug alcohol abuse ( define Investigator ) within 2 year prior inclusion . An MS relapse occur within 30 day prior inclusion ( screen ) AND/OR subject stabilize previous relapse prior inclusion . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Relapsing remit Multiple Sclerosis</keyword>
</DOC>